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Toll-Like Receptor 9 Plays a Pivotal Role in Angiotensin II–Induced
Atherosclerosis
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Background-—Toll-like receptor (TLR) 9 recognizes bacterial DNA, activating innate immunity, whereas it also provokes
inﬂammation in response to fragmented DNA released from mammalian cells. We investigated whether TLR9 contributes to the
development of vascular inﬂammation and atherogenesis using apolipoprotein E–deﬁcient (Apoe/) mice.
Methods and Results-—Tlr9-deﬁcient Apoe/ (Tlr9/Apoe/) mice and Apoe/ mice on a Western-type diet received
subcutaneous angiotensin II infusion (1000 ng/kg per minute) for 28 days. Angiotensin II increased the plasma level of double-
stranded DNA, an endogenous ligand of TLR9, in these mice. Genetic deletion or pharmacologic blockade of TLR9 in angiotensin II–
infused Apoe/ mice attenuated atherogenesis in the aortic arch (P<0.05), reduced the accumulation of lipid and macrophages in
atherosclerotic plaques, and decreased RNA expression of inﬂammatory molecules in the aorta with no alteration of metabolic
parameters. On the other hand, restoration of TLR9 in bone marrow in Tlr9/Apoe/ mice promoted atherogenesis in the aortic
arch (P<0.05). A TLR9 agonist markedly promoted proinﬂammatory activation of Apoe/ macrophages, partially through p38
mitogen-activated protein kinase signaling. In addition, genomic DNA extracted from macrophages promoted inﬂammatory
molecule expression more effectively in Apoe/ macrophages than in Tlr9/Apoe/ macrophages. Furthermore, in humans,
circulating double-stranded DNA in the coronary artery positively correlated with inﬂammatory features of coronary plaques
determined by optical coherence tomography in patients with acute myocardial infarction (P<0.05).
Conclusions-—TLR9 plays a pivotal role in the development of vascular inﬂammation and atherogenesis through proinﬂammatory
activation of macrophages. TLR9 may serve as a potential therapeutic target for atherosclerosis. ( J Am Heart Assoc. 2019;8:
e010860. DOI: 10.1161/JAHA.118.010860.)
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C hronic inﬂammation in the vasculature causesatherosclerosis.1 Although multifactorial in etiology,
accumulating evidence indicates that the innate immune
system plays a role in the development of vascular inﬂam-
mation.2 Immune cells such as macrophages recognize
structures of pathogens through Toll-like receptors (TLRs), a
family of pattern recognition receptors, and activate the
innate immune system for self-defense.3 On the other hand,
recent studies have revealed that macrophages can also
recognize molecules derived from damaged or dead host cells
as endogenous ligands though TLRs, leading to the develop-
ment of chronic sterile inﬂammation.4,5 In fact, activation of
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the innate immune system by endogenous ligands and
subsequent inﬂammation is involved in various diseases.6–8
Several studies have shown that inﬂammation caused by TLR
activation by endogenous ligands participates in the develop-
ment of atherosclerosis.8–10
Recent studies have shown the involvement of TLR9 in
the pathophysiology of various diseases.11 TLR9 expressed in
endosomes recognizes exogenous DNA fragments that
contain unmethylated CpG DNA and plays a role in the
innate immune system.12 In addition, recent evidence has
revealed that TLR9 recognizes cell-free DNA (cfDNA) released
from degenerated host tissues/cells and stimulates inﬂam-
matory cells including macrophages, provoking chronic
sterile inﬂammation. The contribution of cfDNA-TLR9 signal-
ing-associated inﬂammation is reported in several disease
contexts such as autoimmune diseases and others.13–16 We
previously showed that obesity-induced cfDNA released from
adipocytes stimulates chronic adipose tissue inﬂammation
and insulin resistance by stimulating macrophages through
TLR9.17
Atherosclerosis and obesity-induced adipose tissue inﬂam-
mation share chronic inﬂammation as an underlying mech-
anism.18 Previous studies have shown degeneration of
vascular cells including endothelial cells and macrophages
in atherosclerotic lesions,19–22 suggesting the release of
cellular debris that contains various endogenous ligands for
TLRs. However, the role of cfDNA-TLR9 signaling in athero-
genesis remains not fully understood. In this study, we
hypothesized that TLR9 activation by cfDNA released in
atherosclerotic lesions promotes vascular inﬂammation and
atherogenesis. To address our hypothesis, we induced
atherosclerosis in apolipoprotein E–deﬁcient (Apoe/) mice
and Tlr9-deﬁcient Apoe/ (Tlr9/Apoe/) mice. Here, we
infused angiotensin II (Ang II) into both mouse strains to
enhance cell death.23,24 We further investigated the relation-
ship between circulating cfDNA level and coronary plaque
characteristics in patients with acute myocardial infarction
(MI) to obtain translational evidence for cfDNA-TLR9 signaling
in atherogenesis.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Animal Experiments
Apoe/ mice (C57BL/6J background) and Tlr9/ mice
(C57BL/6J background) were originally purchased from the
Jackson Laboratory and Oriental BioService, Inc, respectively.
Tlr9/Apoe/ mice were generated by crossing Apoe/
mice and Tlr9/ mice. Male mice were fed a Western-type
diet (WTD; Oriental Yeast Co Ltd) from 6 weeks of age
through the completion of the experiment. Ang II, 1000 ng/
kg per minute (Wako Pure Chemical Industries, Ltd, Osaka,
Japan) was infused by an osmotic pump (Alzet, Cupertino, CA)
from 2 weeks after starting a WTD, for 4 weeks. For in vivo
TLR9 inhibition, phosphothioate-modiﬁed oligodeoxynu-
cleotide—iODN2088 (50-tcctggcggggaagt-30) was used. Con-
trol (Ctrl)-iODN2088 (50-tcctgagcttgaagt-30) was used as its
control. These oligodeoxynucleotides were synthesized with a
low level of endotoxin (<0.5 endotoxin units/mg; Gene Design
Inc., Osaka, Japan) and intraperitoneally injected into Ang II–
infused Apoe/ mice (150 lg) three times a week for
4 weeks. All mice were housed under a 12-hour light/dark
cycle, with food and water available ad libitum. All experi-
mental procedures conformed to the guidelines for animal
experimentation of Tokushima University. The protocol was
reviewed and approved by our institutional ethics committee.
Bone Marrow Transplantation
Bone marrow (BM) transplantation was performed as
described previously.17 Six-week-old recipient mice were
lethally irradiated (total, 9 Gy). On the following day, unfrac-
tionated BM cells harvested from donor mice were injected
into recipient mice via tail-vein injection. At 2 weeks after BM
transplantation, all mice were started on a WTD, and at
4 weeks after BM transplantation, Ang II infusion was started.
Clinical Perspective
What Is New?
• Angiotensin II infusion to apolipoprotein E-deﬁcient mice
(Apoe/) increased circulating levels of cell-free DNA, a
ligand for TLR9.
• Genetic deletion or pharmacologic blockade of TLR9 atten-
uated atherogenesis in angiotensin II–infused Apoe/ mice
and the activation of TLR9 promoted proinﬂammatory
activation of macrophages.
• The plasma level of cell-free DNA collected from the target
vessel in patients with acute myocardial infarction positively
correlated with inﬂammatory features of target lesions (eg,
lipid arc, macrophage content, and ruptured cavity length/
area), which were determined by optical coherence tomog-
raphy.
What Are the Clinical Implications?
• Inhibiting the cell-free DNA–TLR9 axis attenuates proin-
ﬂammatory activation of macrophages and vascular inﬂam-
mation and might be a potential therapeutic target for
atherosclerotic disease.
DOI: 10.1161/JAHA.118.010860 Journal of the American Heart Association 2
Role of Toll-Like Receptor 9 in Atherogenesis Fukuda et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 26, 2019
Replacement rate after BM transplantation was determined by
ﬂuorescence in situ hybridization of the X and Y chromosomes
in male recipient mice repopulated with female BM as we
described previously.17 We used only BM chimeric mice, in
which >80% of BM had been replaced by donor BM.
Atherosclerotic Lesion Analyses
Atherosclerotic lesions was examined as we reported previ-
ously.25 In brief, mice were euthanized with an overdose of
pentobarbital and perfused with 0.9% sodium chloride solu-
tion. The heart and aorta were removed immediately. The
thoracic aorta was opened longitudinally, and the abdominal
aorta was snap-frozen in liquid nitrogen for further analyses.
The severity of abdominal aortic aneurysm was determined as
reported previously.26 Atherosclerotic lesions in the aortic
arch were determined by en face Sudan IV staining. The
characteristics of atherosclerotic plaques were examined in
frozen sections of lesions in the aortic root (at 5-lm intervals).
Lipid deposition in plaques was determined by oil red O
staining. The expression of vascular cell adhesion molecule-1
(VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1),
and accumulation of macrophages in plaques were examined
by immunohistochemical staining. Sections were incubated
with anti-VCAM-1 antibody (Abcam, Cambridge, MA), anti-
ICAM-1 antibody (Abcam), or anti-Mac3 antibody (BD Bio-
sciences, Bedford, MA), followed by the avidin-biotin complex
technique and stained using a Vector Red substrate kit
(Vector Laboratories, Burlingame, CA). Each section was
counterstained with hematoxylin.
Electron Microscopic Analysis
For immunogold staining, samples were ﬁxed in a 4%
paraformaldehyde solution containing 0.1% glutaraldehyde
and 0.05% Triton X-100 and then embedded in glycol
methacrylate. Ultrathin (80–100 nm) sections were incubated
with 1% bovine serum albumin in 0.01 mol/L PBS for 1 hour
and rinsed with 0.01 mol/L PBS for 15 minutes. The sections
were incubated overnight with anti–single-stranded DNA
(ssDNA) Rabbit IgG Afﬁnity Purify (Immuno-Biological Labora-
tories Co Ltd, Gunma, Japan) at 4°C. After the sections were
washed with 0.01 mol/L PBS, 10-nm gold-labeled goat anti-
rabbit IgG (BBInternational, Cardiff, UK) was applied as the
secondary antibody for 2 hours at room temperature. The
sections were counterstained with uranyl acetate and
Reynold’s lead citrate and then examined under an electron
microscope (H-7600; Hitachi, Tokyo, Japan). As negative
controls for the immunohistochemical procedures, substitu-
tion of an identical concentration of nonimmune IgG for the
primary antibody and direct incubation in colloidal gold
without the primary antibody were performed.
Metabolic Parameter Analyses
At the time of euthanasia, blood was collected into K2-EDTA–
containing tubes, and plasma was stored at 80°C until
required. Plasma lipid levels were measured at LSI Medience
Corporation (Tokyo, Japan). Blood pressure was measured
using a tail-cuff system (BP-98A, Softron, Tokyo, Japan). The
averaged value of three measurements in conscious mice was
used for comparison.
Measurement of Plasma cfDNA Level
cfDNA in plasma was extracted using a QIAamp DNA Mini Kit
(Qiagen, Venlo, the Netherlands). The concentrations of
double-stranded DNA (dsDNA) and ssDNA in extracted cfDNA
were measured using a Quant-iT PicoGreen dsDNA Assay Kit
(Life Technologies, Carlsbad, CA) and QuantiFluor ssDNA
System (Promega, Madison, WI), respectively.
Cell Culture Experiments
Thioglycolate-induced peritoneal macrophages were collected
from female Apoe/ mice and Tlr9/Apoe/ mice at 8 to
10 weeks of age and cultured in Dulbecco’s modiﬁed Eagle’s
medium containing 10% fetal bovine serum. Isolated peri-
toneal macrophages were used for experiments 24 hours
after seeding. Peritoneal macrophages were stimulated with
CpG-ODN1826 (ODN1826), a speciﬁc oligonucleotide that
activates TLR9, or its control (Ctrl-ODN1826) (Gene Design
Inc., Osaka, Japan) for 4 hours to examine gene expression or
for 45 minutes to examine p38 mitogen-activated protein
kinase (MAPK) phosphorylation. To inhibit TLR9 or p38 MAPK,
cells were treated with iODN2088 or SB203580 (Abcam,
Cambridge, MA), respectively. Treated cells were used for
gene expression or protein expression analyses.
Genomic DNA (gDNA) of macrophages was extracted using
a QIAamp DNA Mini Kit (Qiagen, Venlo, the Netherlands), and
transfected into Apoe/ macrophages or Tlr9/Apoe/
macrophages using Lipofectamine LTX with PlusTM Reagent
(Thermo Fisher Scientiﬁc, Waltham, MA) according to the
manufacturer’s instructions.
Real-Time Reverse-Transcription Polymerase
Chain Reaction
cDNA was synthesized using a QuantiTect Reverse Transcrip-
tion kit (Qiagen, Venlo, the Netherlands) from total RNA
extracted from tissues or cells using an illustra RNAspin RNA
Isolation Kit (GE Healthcare, Chicago, IL). Quantitative real-
time polymerase chain reaction (qPCR) was performed on
Mx3000P (Agilent Technologies, Santa Clara, CA) using gene-
speciﬁc primers (Table S1) and Power SYBR Green PCR
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Master Mix (Applied Biosystems, Foster City, CA). Data are
expressed in arbitrary units normalized by b-actin.
Western Blotting Analysis
Lysates prepared from cells or aorta in RIPA buffer (Wako
Pure Chemical Industries, Ltd, Osaka, Japan) containing a
protease inhibitor cocktail (Roche, Basel, Switzerland) and a
phosphatase inhibitor cocktail (Thermo Fisher Scientiﬁc) were
separated on SDS–polyacrylamide gel electrophoresis gels.
The following antibodies were used: anti-TLR9, anti-VCAM-1
(Abcam, Cambridge, MA), anti-p38 MAPK, anti-phospho-p38
MAPK (Cell Signaling, Danvers, MA), and anti-b-actin (Sigma,
Fukushima, Japan). Levels of expression were quantiﬁed by
densitometry (ImageQuant LAS 4000mini; GE Healthcare Life
Sciences, Little Chalfont, England).
Enzyme Linked Immunosolvent Assay
To detect proinﬂammatory activation of macrophages, we
performed ELISA using culture supernatant of macrophages:
Apoe/ macrophages or Tlr9/Apoe/ macrophages
were cultured with ODN1826 or Ctrl-ODN1826 for 24 hours,
and then culture supernatant was collected after centrifuga-
tion and ﬁltration through a 20-lm mesh to remove
cell debris. Levels of monocyte chemoattractant protein-1
(MCP-1) and tumor necrosis factor-a (TNF-a) in culture
supernatant were measured using commercially available kit
(Proteintech, Chicago, IL).
Clinical Research
We included patients with acute MI including both ST-segment
elevation MI or non–ST-segment elevation MI who underwent
emergency percutaneous coronary intervention and optical
coherence tomography (OCT) study of the vessel undergoing
percutaneous coronary intervention at Wakayama Medical
University Hospital. The diagnostic criteria for these disease
conditions were described in the previous study.27 Patients
with hemodynamic shock, renal insufﬁciency with baseline
creatinine >1.6 mg/dL (or estimated glomerular ﬁltration rate
<35 mL/min per 1.73 m2), known systemic inﬂammatory
conditions requiring corticosteroid therapy, evidence of active
infectious diseases, a left main coronary artery lesion, an
extremely tortuous vessel, or reference vessel diameter
>4 mm were excluded. In addition, we excluded patients
with poor OCT images. This protocol was approved by the
Wakayama Medical University Ethics Committee. All patients
provided written informed consent before participation. This
study was in compliance with the Declaration of Helsinki with
regard to investigations on humans.
Primary percutaneous coronary intervention was per-
formed in all patients. Coronary angiography was performed
using a 5-Fr Judkins-type catheter via the femoral or radial
approach. All patients received oral aspirin, an intravenous
bolus injection of 5000 U heparin, and intracoronary
isosorbide dinitrate before angiography. After completion of
diagnostic angiography, the culprit lesion was identiﬁed on
the basis of coronary angiography ﬁndings as well as those
of electrocardiography and echocardiography. Before manual
thromboaspiration, blood was collected from coronary arter-
ies using an aspiration catheter (Export; Medtronic Japan,
Tokyo, Japan). All samples were immediately centrifuged at
3000g for 15 minutes, and then stored at 80°C. Following
thromboaspiration, frequency domain OCT (ILUMIEN and
ILUMIEN OPTIS, St. Jude Medical, Minnesota, USA; or
LUNAWAVE, Terumo, Tokyo, Japan) was used to observe
the culprit lesion morphology. No patients were administered
glycoprotein IIa/IIIb inhibitors because their use is not
approved in Japan.
All OCT images were analyzed using commercially
available ofﬂine OCT consoles as described previously.27
For OCT image analysis, consensus reading was performed
by 2 experienced OCT investigators (A.T. and T.N.) who
were blinded to the angiographic and clinical data.
Macrophages were assessed using a previously reported
technique.28 In short, macrophage accumulation was
deﬁned as high-intensity, signal-rich linear regions with
sharp attenuation. Maximum lipid arc was also measured.29
The cross-sectional area of the ruptured cavity at the site
of the largest intraplaque cavity and longitudinal cavity
length were measured according to the previous study.30
Four patients were excluded from the analysis of cavity
area/length because clear cavity images were not obtained
because of thrombi.
Statistical Analyses
All numerical values are expressed as meanSEM. Com-
parison of parameters between 2 groups was performed
with unpaired Student t test when data showed a normal
distribution or with Mann–Whitney U test when data did
not show a normal distribution. The utilized nonparametric
test (Mann–Whitney) is based on ranks and thus less
sensitive to the magnitude of outliers. The severity of
abdominal aortic aneurysm and survival curve between the
2 strains were analyzed by Mann–Whitney U test and
Kaplan–Meier method with log-rank test, respectively.
Univariate analysis between plaque characteristics and
plasma dsDNA or ssDNA level was performed using
Spearman’s rank correlation coefﬁcient. A value of
P<0.05 was considered signiﬁcant.
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Results
Angiotensin II Increases Circulating cfDNA in
Plasma and TLR9 Expression in Atherosclerotic
Aorta
To stimulate cell death and atherogenesis, we administered
Ang II to animals. Ang II infusion for 4 weeks signiﬁcantly
elevated circulating level of dsDNA in both Apoe/ mice and
Tlr9/Apoe/ mice, and ssDNA in Tlr9/Apoe/ mice
(Figure 1A and 1B). Ang II infusion also increased the
expression of TLR9, a receptor for cfDNA, at the RNA and
protein level in the atherosclerotic aorta in Apoe/ mice
(Figure 1C and 1D). Immunoelectron microscopic analysis
using atherosclerotic plaques demonstrated accumulation of
ssDNA in the cytoplasm of macrophages, suggesting that
macrophages take up cfDNA in atherosclerotic lesions
(Figure 1E).
Genetic Deletion of TLR9 in Apoe/ Mice
Attenuates Vascular Inﬂammation and
Atherogenesis
We compared atherosclerotic lesion progression in the
aortic arch between Apoe/ mice and Tlr9/Apoe/
mice after 4 weeks of Ang II infusion. Blood pressure and
levels of lipids such as total cholesterol, high-density
lipoprotein cholesterol, and triglyceride were comparable
between the two mouse strains (Table 1). The results of
en face Sudan IV staining demonstrated a signiﬁcant
reduction in atherosclerotic lesions in Tlr9/Apoe/
mice compared with Apoe/ mice (Figure 2A). The
results of qPCR analysis indicated that genetic deletion
of TLR9 reduced the expression of inﬂammatory molecules
such as VCAM-1 (P<0.05), ICAM-1 (P<0.01), and MCP-1
(P<0.05) in the aorta. Deletion of Tlr9 tended to decrease
the expression of TNF-a and F4/80, a macrophage
marker, in the aorta (Figure 2B). Oil red O staining of
atherosclerotic plaques in the aortic root demonstrated
that Tlr9 deﬁciency decreased lipid deposition in plaques
in Apoe/ mice (P<0.01) (Figure 3A). Immunohistochem-
ical analysis showed that the expression of VCAM-1
(P<0.001) and ICAM-1 (P<0.05) was lower in Tlr9/
Apoe/ mice than in Apoe/ mice (Figure 3B and
3C). Also, inﬁltration of macrophages into atherosclerotic
plaques determined by Mac3 staining was reduced in
Tlr9/Apoe/ mice compared with Apoe/ mice
(P<0.05) (Figure 3D). These results suggested reduced
vascular inﬂammation in Tlr9/Apoe/ mice compared
with Apoe/ mice. There was no signiﬁcant difference in
the severity of aortic aneurysm and survival between 2
strains of mice in this study (Figure S1).
Administration of TLR9 Antagonist Attenuates
Vascular Inﬂammation and Atherogenesis in
Apoe/ Mice
To conﬁrm the role of TLR9 in the development of vascular
inﬂammation and atherosclerosis in Ang II–infused Apoe/
mice, we examined whether pharmacologic inhibition of TLR9
attenuates vascular inﬂammation and atherogenesis. Admin-
istration of an inhibitory oligonucleotide of TLR9, iODN2088,
signiﬁcantly suppressed atherosclerotic lesion development in
Apoe/ mice compared with its control as determined by en
face Sudan IV staining in the aortic arch (P<0.05) (Figure 4A).
iODN2088 did not alter metabolic parameters including blood
pressure and plasma lipid levels (Table 2). The results of qPCR
analysis showed that iODN2088 treatment decreased the
expression of inﬂammatory molecules, such as ICAM-1 and
MCP-1, and a macrophage marker in the atherosclerotic aorta
(Figure 4B). Histologic analyses demonstrated that inhibition
of TLR9 reduced the expression of VCAM-1 (P<0.01) and
macrophage accumulation (P<0.001) in atherosclerotic pla-
ques in Apoe/ mice. iODN2088 treatment decreased lipid
deposition and ICAM-1 expression, although these did not
reach statistical signiﬁcance (Figure 5A through 5D). These
results suggested that in vivo TLR9 blockade partially
attenuates the development of vascular inﬂammation and
atherosclerosis.
Restoration of TLR9 in BM Stimulates
Atherogenesis in Tlr9/Apoe/ Mice
Immune cells such as macrophages are the major population
which expresses TLR9. Therefore, to examine the role of TLR9
in atherogenesis, we restored TLR9 in BM in Tlr9/Apoe/
mice. Atherosclerotic lesion development under Ang II
infusion was signiﬁcantly greater in mice that express TLR9
in BM than mice that lack TLR9 in BM (P<0.05) (Figure 6A).
We also examined the expression of inﬂammatory molecules
in the aorta. The expression of a macrophage marker was
signiﬁcantly higher in the mice that have TLR9 in BM
compared with the mice that lack TLR9 in BM (P<0.05). The
expression of other inﬂammatory molecules showed the same
tendency; however, it did not reach statistical signiﬁcance
(Figure 6B). There were no differences in metabolic param-
eters between these mice (Table 3).
TLR9 Signaling Promotes Macrophage Activation
We investigated the role of TLR9 in macrophage activation, an
essential feature of vascular inﬂammation and atherogenesis.
TLR9 activation by ODN1826, a TLR9 agonist, promoted the
expression of inﬂammatory molecules such as VCAM-1 and
ICAM-1 in Apoe/ macrophages, but not in Tlr9/Apoe/
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Figure 1. Angiotensin II increases circulating cfDNA and TLR9 expression in atherosclerotic aorta. A and B,
Ang II infusion for 4 weeks to WTD-fed Apoe/ mice and Tlr9/Apoe/ mice increased circulating cfDNA
as determined by dsDNA and ssDNA (n=12–18). Comparison between Ang II-treated group and vehicle-treated
group in each strain was performed with Mann–Whitney U test. C and D, Ang II infusion for 4 weeks to WTD-
fed Apoe/ mice promoted TLR9 expression at the RNA (C) and protein (D) level in the atherosclerotic aorta.
Comparison between Ang II–treated group and vehicle-treated group was performed with Mann–Whitney U test.
E, Representative immunogold staining against ssDNA demonstrated the accumulation of gold particles (10 nm)
in the cytoplasm of macrophages (arrows) in atherosclerotic lesions obtained from WTD-fed Apoe/ mice.
Scale bar, 500 nm. Inset: lower magniﬁcation (scale bar, 2 lm). *P<0.05 and **P<0.01. All values are
meanSEM. Ang II indicates angiotensin II; cfDNA, cell-free DNA; dsDNA, double-stranded DNA; ssDNA, single-
stranded DNA; TLR9, Toll-like receptor 9; WTD, Western-type diet.
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macrophages (Figure 7A). iODN2088, a speciﬁc antagonist of
TLR9, completely inhibited these responses (Figure S2).
Proinﬂammatory activation of macrophages was also con-
ﬁrmed at the protein level (Figure 7B and 7C).
TLR9 is a receptor for DNA fragments released from degen-
erated cells. Therefore,we prepared gDNA frommacrophages and
transfected it into Apoe/ or Tlr9/Apoe/ macrophages.
gDNApromoted inﬂammatorymolecule (eg, VCAM-1, ICAM-1, and
Table 1. Effect of Genetic Deletion of TLR9 on Metabolic Parameters
Apoe/ Tlr9/Apoe/ P Value
Body weight, g 29.91.0 29.50.7 0.72
Heart rate, bpm 71310 70115 0.58
Systolic blood pressure, mm Hg 134.64.3 126.42.8 0.19
Diastolic blood pressure, mm Hg 88.22.9 83.42.9 0.25
Total cholesterol, mg/dL 1361.775.8 1251.8105.3 0.51
Triglyceride, mg/dL 168.915.8 190.724.3 0.46
HDL cholesterol, mg/dL 20.62.3 20.01.6 0.85
All values are meanSEM. HDL indicates high-density lipoprotein; TLR9, Toll-like receptor 9.
Apoe-/- Tlr9-/-Apoe-/-A
B
Figure 2. Genetic deletion of TLR9 in Apoe/ mice attenuates atherogenesis and vascular
inﬂammation. A, En face Sudan IV staining of the aortic arch showed that Tlr9/Apoe/ mice had
reduced atherosclerotic lesions compared with Apoe/ mice (n=19–20). Bar: 1 mm. B, qPCR analysis
using the abdominal aorta revealed that genetic deletion of TLR9 decreased the expression of
inﬂammatory molecules such as VCAM-1, ICAM-1, and MCP-1. TLR9 deletion tended to reduce the
expression of TNF-a and F4/80, a macrophage marker, in the atherosclerotic aorta (n=13–14).
*P<0.05 and **P<0.01. All comparisons between Tlr9/Apoe/ mice and Apoe/ mice were
performed with Mann–Whitney U test. All values are meanSEM. ICAM-1 indicates intercellular cell
adhesion molecule-1; MCP-1, monocyte chemoattractant protein-1; qPCR, quantitative real-time
polymerase chain reaction; TLR9, Toll-like receptor 9; TNF- a, tumor necrosis factor-a; VCAM-1,
vascular cell adhesion molecule-1.
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Apoe-/- Tlr9-/-Apoe-/-
A
B
C
D
Figure 3. Genetic deletion of TLR9 in Apoe/ mice reduces inﬂammatory molecule expression in
atherosclerotic plaques. A, Oil red O staining of atherosclerotic plaques in the aortic root. Lipid deposition in
plaques was decreased in Tlr9/Apoe/ mice compared with that in Apoe/ mice (n=11–16). Bar:
100 lm. B through D, Immunostaining against VCAM-1 (B), ICAM-1 (C), and Mac3 (D). Genetic deletion of
TLR9 reduced the expression of adhesion molecules and accumulation of macrophages in atherosclerotic
plaques in Apoe/ mice (n=13–16). Bar: 100 lm. *P<0.05, **P<0.01, and ***P<0.001. All comparisons
between Tlr9/Apoe/ mice and Apoe/ mice were performed with unpaired Student t test. All values are
meanSEM. ICAM-1 indicates intercellular cell adhesion molecule-1; TLR9, Toll-like receptor 9; VCAM-1,
vascular cell adhesion molecule-1.
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MCP-1) expression more effectively in Apoe/ macrophages
than in Tlr9/Apoe/ macrophages (Figure 7D).
The results of Western blotting analysis showed that
ODN1826 increased the phosphorylation of p38 MAPK in
Apoe/ macrophages (Figure 8A and Figure S3). Further-
more, a p38 MAPK inhibitor, SB203580, attenuated
ODN1826-induced expression of inﬂammatory molecules
(Figure 8B). These results indicated that activation of MAPK
signaling participates in the TLR9-mediated inﬂammatory
response of macrophages at least partially.
Circulating cfDNA Is Associated With Plaque
Vulnerability in Humans
To investigate the clinical signiﬁcance of cfDNA, we examined
the relationship between plaque characteristics determined by
OCT and circulating cfDNA in the coronary artery in patients
with acute MI. The patients’ background is summarized in
Table 4. Mean age of the participants was 70.01.8 years;
64% were male. dsDNA level positively correlated with lipid arc
(Spearman q=0.32; P<0.05) and macrophage grade (Spear-
man q=0.32; P<0.05). dsDNA level also correlated with cavity
length (Spearman q=0.46; P<0.01) and tended to correlate
with cavity area (Spearman q=0.31; P=0.07) in coronary artery
plaques (Figure 9A through 9D). ssDNA level signiﬁcantly
correlated with lipid arc (Spearman q=0.36; P<0.05) and cavity
length (Spearman q=0.36; P<0.05), and tended to correlate
with macrophage grade and cavity area (Figure 9E through
9H). These results indicated that cfDNA level is associated with
the features of vulnerable atherosclerotic plaques, implying
participation of cfDNA-TLR9 signaling in the development of
vascular inﬂammation in coronary arteries in humans.
A
B
iODNCtrl-iODN
Figure 4. Administration of TLR9 antagonist attenuates atherogenesis and vascular inﬂammation
in Apoe/ mice. A, En face Sudan IV staining of the aortic arch showed that administration of
iODN2088, an inhibitory oligonucleotide for TLR9, to Ang II–infused Apoe/ mice reduced
atherosclerotic lesion development compared with control oligonucleotide administration, Ctrl-
iODN (n=7–8). Bar: 1 mm. B, qPCR analysis using abdominal aorta revealed that iODN2088
treatment decreased the expression of inﬂammatory molecules such as VCAM-1, ICAM-1, and MCP-
1. TLR9 deletion also reduced the expression of F4/80, a macrophage marker, and TNF-a in the
atherosclerotic aorta (n=7–8). *P<0.05 and **P<0.01. All comparisons between iODN2088-treated
group and Ctrl-iODN–treated group were performed with Mann–Whitney U test. All values are
meanSEM. ICAM-1 indicates intercellular cell adhesion molecule-1; MCP-1, monocyte chemoat-
tractant protein-1; qPCR, quantitative real-time polymerase chain reaction; TLR9, Toll-like receptor
9; TNF- a, tumor necrosis factor-a; VCAM-1, vascular cell adhesion molecule-1.
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Discussion
Accumulating evidence suggests that atherosclerosis is a
chronic inﬂammatory disease1; however, the mechanism of
vascular inﬂammation and atherogenesis is not fully under-
stood. In this study, we demonstrated that Ang II treatment
increased the level of plasma cfDNA, an endogenous ligand
for TLR9. Also, genetic deletion of TLR9 or pharmacologic
blockade of TLR9 revealed that TLR9 plays a pivotal role in the
development of vascular inﬂammation and atherogenesis in
Ang II–infused Apoe/ mice. On the other hand, restoration
of TLR9 in BM promoted atherogenesis in TLR9-deﬁcient
mice. Results of in vitro experiments showed that TLR9
activation promotes proinﬂammatory activation of macro-
phages via p38 MAPK at least partially, supporting the results
of our in vivo studies. Furthermore, in our clinical study,
circulating cfDNA level in the coronary artery was associated
with vulnerable features of atherosclerotic plaques in the
coronary artery. These results suggested the participation of
cfDNA-TLR9 signaling in the development of vascular inﬂam-
mation and atherosclerosis.
TLR activation by endogenous ligands released as damage-
associated molecular patterns in response to various risk
factors has attracted much attention as a possible mechanism
of vascular inﬂammation and atherosclerosis.9,15 For example,
previous studies have reported that activation of TLR2 or TLR4
by their endogenous ligands, such as fatty acids, lipoproteins,
and heat shock proteins, promotes atherogenesis.31–33
Recent studies including our own have suggested that TLR9
recognizes cfDNA as an endogenous ligand, promoting
chronic inﬂammation.11,16,17 However, the role of TLR9 in
atherogenesis is still controversial.
In the present study, we found that Ang II infusion into
Apoe/ mice increased the expression of Tlr9 in the aorta.
Also, immunoelectron microscopic analysis demonstrated the
accumulation of ssDNA in macrophages in atherosclerotic
lesions. Therefore, to test the hypothesis that the cfDNA-TLR9
pathway plays a pivotal role in the progression of vascular
inﬂammation in vivo, we employed 3 mouse models. In
addition, we infused Ang II into animals to enhance vascular
damage, which accelerates release of cfDNA.23,24 In fact, Ang
II infusion increased plasma cfDNA in both mouse strains.
Genetic deletion of TLR9 attenuated the development of
vascular inﬂammation and atherogenesis in Apoe/ mice
under Ang II infusion. Pharmacologic blockade of TLR9 using a
speciﬁc TLR9 antagonist also suppressed vascular inﬂamma-
tion and atherogenesis in Ang II–infused Apoe/ mice. On
the other hand, restoration of TLR9 in BM promoted
atherogenesis partially in TLR9-deﬁcient animals under Ang
II infusion. These results demonstrated that TLR9 stimulates
atherosclerosis in Apoe/ mice, at least partially, under an
Ang II–infused condition. To investigate the mechanism, we
examined the role of TLR9 in proinﬂammatory activation of
macrophages, a key player in atherogenesis.34,35 Ligation of a
TLR9 agonist to macrophages promoted expression of
inﬂammatory molecules such as TNF-a, ICAM-1, and VCAM-
1. TLR9-deﬁcient macrophages did not show this response.
The increase of adhesion molecules in Apoe/ macrophages
may explain the increase of macrophage inﬁltration into
plaques. We further transfected gDNA extracted from
macrophages into Apoe/ and Tlr9/Apoe/ macro-
phages. Previous studies have shown the degradation of
vascular cells such as endothelial cells or smooth muscle cells
in atherosclerotic lesions,19 whereas recent studies also
demonstrated degradation of macrophages in lesions, which
is associated with the progression or vulnerability of
atherosclerotic plaques.22 gDNA more strongly promoted
inﬂammatory molecule expression in Apoe/ macrophages
than in Tlr9/Apoe/ macrophages. We also found that
TLR9 activation increased the phosphorylation of p38 MAPK
signaling, an important pathway for inﬂammatory activa-
tion,36,37 in Apoe/ macrophages. This result is consistent
with previous studies demonstrating a link between TLR9 and
MAPK.38 In fact, a p38 MAPK inhibitor attenuated the
expression of inﬂammatory molecules induced by a TLR9
agonist in Apoe/ macrophages. These results suggested
Table 2. Effect of Pharmacologic Blockade of TLR9 on Metabolic Parameters
Ctrl-iODN2088 iODN2088 P Value
Body weight, g 33.90.9 32.31.1 0.31
Heart rate, bpm 69612 72115 0.21
Systolic blood pressure, mm Hg 143.48.1 139.56.6 0.70
Diastolic blood pressure, mm Hg 88.92.3 91.44.5 0.64
Total cholesterol, mg/dL 1250.784.5 1060.6173.6 0.36
Triglyceride, mg/dL 135.421.7 161.432.7 0.53
HDL cholesterol, mg/dL 20.11.1 18.33.5 0.64
All values are meanSEM. HDL indicates high-density lipoprotein; TLR9, Toll-like receptor 9.
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iODNCtrl-iODN
A
B
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Figure 5. Administration of TLR9 antagonist reduces inﬂammatory molecule expression in atherosclerotic
plaques. A, Oil red O staining of atherosclerotic plaques in the aortic root. iODN2088 reduced lipid deposition
in atherosclerotic plaques compared with Ctrl-iODN; however, this did not reach statistical signiﬁcance (n=7–
8). Bar: 100 lm. B through D, Immunostaining against VCAM-1 (B), ICAM-1 (C), and Mac3 (D). iODN2088
reduced the expression of VCAM-1 and the accumulation of macrophages in atherosclerotic plaques compared
with Ctrl-iODN (n=7–8). Bar: 100 lm. **P<0.01 and ***P<0.001. All comparisons between iODN2088-
treated group and Ctrl-iODN–treated group were performed with unpaired Student t test. All values are
meanSEM. ICAM-1 indicates intercellular cell adhesion molecule-1; TLR9, Toll-like receptor 9; TNF- a, tumor
necrosis factor-a; VCAM-1, vascular cell adhesion molecule-1.
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that cfDNA-TLR9 signaling stimulates proinﬂammatory acti-
vation of macrophages and the development of atheroscle-
rosis. Some previous studies have demonstrated that
pharmacologic inactivation or activation of TLR9 in Apoe/
mice suppressed or promoted atherosclerotic lesion develop-
ment, respectively, indicating a proatherogenic role of
Tlr9-/-Apoe-/-
↓
Tlr9-/-Apoe-/-
Apoe-/-
↓
Tlr9-/-Apoe-/-
A
B
Figure 6. Restoration of TLR9 in BM promotes atherogenesis in Tlr9/Apoe/ mice. A, En
face Sudan IV staining of the aortic arch showed that restoration of TLR9 in BM promoted
atherogenesis in Tlr9/Apoe/ mice under Ang II infusion (n=9–10). Bar: 1 mm. B, qPCR
analysis using abdominal aorta revealed that restoration of TLR9 in BM promoted the expression
of a macrophage marker, F4/80 (n=9–10). *P<0.05. All comparisons between two BM-chimeric
mice were performed with Mann–Whitney U test. All values are meanSEM. BM indicates bone
marrow; ICAM-1, intercellular cell adhesion molecule-1; MCP-1, monocyte chemoattractant
protein-1; qPCR, quantitative real-time polymerase chain reaction; TLR9, Toll-like receptor 9.
Table 3. Effect of Restoration of TLR9 in Bone Marrow on Metabolic Parameters
Donor Tlr9/Apoe/ Apoe/
P Value
↓ ↓ ↓
Recipient Tlr9/Apoe/ Tlr9/Apoe/
Body weight, g 26.60.8 25.61.0 0.45
Heart rate, bpm 65631 68031 0.59
Systolic blood pressure, mm Hg 138.94.3 136.94.3 0.75
Diastolic blood pressure, mm Hg 93.64.4 87.64.9 0.38
Total cholesterol, mg/dL 1407.6295.8 1884.581.1 0.11
Triglyceride, mg/dL 145.134.8 168.620.3 0.57
HDL cholesterol, mg/dL 20.43.8 19.01.4 0.74
All values are meanSEM. HDL indicates high-density lipoprotein; TLR9, Toll-like receptor 9.
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TLR9.39,40 The results of our present study are consistent with
previous studies and provide the mechanism for TLR9
activation in atherosclerosis partially.
On the other hand, a recent study by Koulis et al
demonstrated antiatherogenic roles of TLR9 by using a
genetic deletion model of TLR9 in Apoe/ mice.41 In that
study, not only genetic deletion but also administration of
ODN1668, another TLR9 agonist, inhibited atherosclerotic
lesion development in Apoe/ mice on a WTD. In that
study, atherosclerosis was induced by long-term WTD
feeding but not Ang II. While, in our present study, we
infused Ang II to enhance cellular damage and in fact,
cfDNA, potential TLR9 ligands, levels increased in Ang II–
infused animals. A previous study suggested different roles
of TLR9 activation according to the concentration of its
ligand.42 The difference in levels of TLR9 ligands attributable
to the use of different mouse models might be one of the
reasons for the discrepancy. Also, in the study by Koulis
et al, total cholesterol was higher in Tlr9/Apoe/ mice
with an unknown mechanism; however, in the present study,
there was no difference in plasma lipid levels between
Apoe/ mice and Tlr9/Apoe/ mice. This might
Figure 7. TLR9 signaling promotes macrophage activation. A, ODN1826 (100 nmol/L), a TLR9-speciﬁc ligand, increased the expression
of inﬂammatory molecules, such as VCAM-1, ICAM-1, MCP-1, and TNF-a in peritoneal macrophages obtained from Apoe/ mice, but not
in macrophages obtained from Tlr9/Apoe/ mice (n=6). B, Western blotting demonstrated that TLR9 activation with ODN1826
(100 nmol/L) increased the expression of VCAM-1 in Apoe/ macrophages, but not in Tlr9/Apoe/ macrophages (n=5). C, ELISA
demonstrated that TLR9 activation with ODN1826 (100 nmol/L) increased TNF-a and MCP-1 in supernatant of Apoe/ macrophages,
but not in that of Tlr9/Apoe/ macrophages (n=5). D, Transfection of gDNA promoted the expression of VCAM-1, ICAM-1, and MCP-1
in Apoe/ macrophages, but not in Tlr9/Apoe/ macrophages (n=5–6). *P<0.05 and **P<0.01. A through C, Comparisons between
ODN1826-treated group and Ctrl-ODN1826-treated group in each mouse strain were performed with Mann–Whitney U test. D,
Comparisons between Tlr9/Apoe/ macrophages and Apoe/ macrophages were performed with Mann–Whitney U test. All values
are meanSEM. gDNA indicates genomic DNA; ICAM-1, intercellular cell adhesion molecule-1; MCP-1, monocyte chemoattractant
protein-1; qPCR, quantitative real-time polymerase chain reaction; TLR9, Toll-like receptor 9; TNF- a, tumor necrosis factor-a; VCAM-1,
vascular cell adhesion molecule-1.
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contribute to the discrepancy. Similar to that study, in this
study, Tlr9/Apoe/ mice had larger atherosclerotic
lesions compared with Apoe/ mice under vehicle infusion
condition, although blood lipid levels were equivalent
between 2 strains of mice (Figure S4 and Table S2). Thus,
we speculate that the role of TLR9 in the development of
vascular inﬂammation and atherogenesis may differ accord-
ing to the disease conditions. However, in addition to in vivo
studies, in our present study, we demonstrated a proinﬂam-
matory role of TLR9 in macrophage activation, which
supports our in vivo data. These results suggest the
proatherogenic roles of cfDNA-TLR9 signaling, at least in
an Ang II–infused condition. Further studies are needed to
elucidate the contribution of cfDNA-TLR9 signaling to
atherogenesis and its mechanism.
Finally, in this study, we examined the association between
plasma cfDNA level and plaque characteristics determined by
OCT in patients with acute MI who underwent percutaneous
coronary intervention. OCT is a high-resolution imaging
Figure 8. Inhibition of p38 MAPK suppresses TLR9-induced
macrophage activation. A, Ligation of ODN1826 (100 nmol/L)
to TLR9 activated the MAPK pathway determined by the
phosphorylation of p38 MAPK in Apoe/ macrophages (n=4–
5). Comparison between ODN1826-treated group and Ctrl-
ODN1826–treated group was performed with Mann–Whitney U
test. B, The p38 MAPK inhibitor, SB203580 (10 lmol/L),
abrogated the expression of inﬂammatory molecules, such as
VCAM-1, ICAM-1, MCP-1, and TNF-a, which are induced by TLR9
activation with ODN1826 (100 nmol/L) in Apoe/ macro-
phages (n=6). Effects of SB203580 in ODN1826-treated
macrophages were analyzed with Mann–Whitney U test.
*P<0.05 and **P<0.01. All values are meanSEM. ICAM-1
indicates intercellular cell adhesion molecule-1; MAPK, mitogen-
activated protein kinase; MCP-1, monocyte chemoattractant
protein-1; qPCR, quantitative real-time polymerase chain reac-
tion; TLR9, Toll-like receptor 9; TNF- a, tumor necrosis factor-a;
VCAM-1, vascular cell adhesion molecule-1.
Table 4. Patients’ Characteristics
N=39
Age, y 70.01.8
Male sex 25 (64)
Hypertension 30 (77)
Dyslipidemia 23 (59)
Diabetes mellitus 13 (33)
Current smoking 17 (44)
Obesity (BMI >25) 12 (31)
Family history of CAD 8 (21)
OMI 2 (5)
STEMI/NSTEMI 29/10 (74/26)
Multivessel disease 21 (54)
Total cholesterol, mg/dL 168.65.0
LDL cholesterol, mg/dL 98.34.4
HDL cholesterol, mg/dL 43.92.4
Triglyceride, mg/dL 87.39.1
HbA1c, % 6.40.2
Glucose, mg/dL 172.711.2
CK on admission, IU/mL 350.6120.0
Peak CK, IU/mL 2140.2311.5
CCB 16 (41)
RAS-I 12 (31)
b-blocker 2 (5)
Statin 7 (18)
Anti-DM 6 (15)
Insulin 2 (5)
All values are n (%) or meanSEM. BMI, body mass index; CAD, coronary artery disease;
CCB, calcium channel blocker; CK, creatine kinase; DM, diabetes mellitus; HbA1c,
hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSTEMI, non
–ST-segment elevation myocardial infarction; OMI, old myocardial infarction; RAS-I, renin
–angiotensin system inhibitor, STEMI, ST-segment elevation myocardial infarction.
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technique for plaque characterization,29 and allows us to
assess the features of vulnerable plaques, which are associ-
ated with the inﬂammatory process in the vasculature.43 A
previous study showed that patients with severe coronary
artery disease as assessed by coronary computed tomo-
graphic angiography have higher plasma dsDNA level,
Figure 9. Plasma cfDNA levels positively correlate with inﬂammatory features of
coronary atherosclerosis. Plasma dsDNA or ssDNA level in the target coronary artery
positively correlated with inﬂammatory features of coronary atherosclerosis, such as lipid
arc (A and E) and macrophage grade (B and F) determined by OCT (n=39). Plasma
dsDNA or ssDNA level in the target coronary artery also showed a positive correlation
with cavity area (C and G) or length (D and H) in ruptured coronary artery plaques
(n=35). Univariate analysis between plaque characteristics and plasma dsDNA or ssDNA
level was performed using Spearman’s rank correlation coefﬁcient. cfDNA indicates cell-
free DNA; dsDNA, double-stranded DNA; OCT, optical coherence tomography; ssDNA,
single-stranded DNA.
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suggesting inﬂammatory properties of released DNA frag-
ments.44 In this study, we further demonstrated that the
plasma level of cfDNA collected from the target vessel in
acute MI patients positively correlated with lipid arc,
macrophage content, and ruptured cavity length/area, all of
which are associated with plaque inﬂammation. Furthermore,
a previous study demonstrated the expression of TLR9 in
atherosclerotic lesions in humans.10 Therefore, the results of
our clinical study suggested that cfDNA-TLR9 signaling
contributes to the development of vascular inﬂammation in
humans, at least partially. Recent studies demonstrated that
other DNA sensors may contribute to the pathophysiology of
various inﬂammatory diseases. Therefore, an inﬂammatory
process mediated by other DNA sensors may also be involved
in the development of vascular inﬂammation in the coronary
artery. Further studies are required to elucidate the role of
DNA sensors such as TLR9 in atherogenesis.
Recent studies have suggested that damage-associated
molecular patterns contribute to the development of chronic
inﬂammatory diseases as endogenous ligands that activate
the innate immune system.5 The present study demonstrated
that TLR9, originally known as a sensor for exogenous DNA
fragments, contributes to proinﬂammatory activation of
macrophages and the development of vascular inﬂammation
and atherosclerosis in Apoe/ mice that receive Ang II
infusion. In addition, the results of our clinical study
suggested that cfDNA positively correlates with the features
of plaque inﬂammation in patients with acute MI. Thus, the
cfDNA-TLR9 axis participates in the pathogenesis of vascular
inﬂammation and atherogenesis and, might be a therapeutic
target for atherosclerotic disease.
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Table S1. Primer sequences. 
 
 
 
  
  Forward  Reverse 
F4/80 5’- TGCATCTAGCAATGGACAGC -3’ 5’- GCCTTCTGGATCCATTTGAA -3’ 
ICAM-1 5’- TTCACACTGAATGCCAGCTC -3’ 5’- GTCTGCTGAGACCCCTCTTG -3’ 
MCP-1 5'-CCACTCACCTGCTGCTACTCAT-3’ 5'-TGGTGATCCTCTTGTAGCTCTCC-3’ 
TLR9 5'-ATGGACGGGAACTGCTACTACA-3’ 5'-GACCTTGGAACCAGGAAGAGTT-3’ 
TNF-α 5'-ACCCTCACACTCAGATCATCTTC-3’ 5'-TGGTGGTTTGCTACGACGT-3’ 
VCAM-1 5'-GCCCATCCTCTGTGACTCAT-3’ 5'-AGGCCACAGGTATTTTGTCG-3’ 
β-actin 5'-CCTGAGCGCAAGTACTCTGTGT-3’ 5'-GCTGATCCACATCTGCTGGAA-3’ 
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Table S2. Effect of genetic deletion of TLR9 on metabolic parameters in vehicle 
infused mice. 
    
 Apoe-/- Tlr9-/-Apoe-/- P-value 
Body weight, g 31.7±0.8 31.8±1.1 0.72  
Heart rate, bpm 750±5 725±12 0.05  
Systolic blood pressure, mmHg 100.6±2.6 98.0±2.2 0.56  
Diastolic blood pressure, mmHg 64.7±1.9 58.6±2.3 0.05  
Total choletesterol, mg/dl 1034.9±80.4 1193.1±135.4 0.29  
Triglyceride, mg/dl 140.9±10.9 150.0±23.1 0.71  
HDL cholesterol, mg/dl 20.6±1.5 20.1±2.4 0.86  
    
All values are mean ± SEM. HDL; high-density lipoprotein  
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Figure S1. Effect of genetic deletion of TLR9 on abdominal aortic aneurysm formation and 
survival curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic deletion of TLR9 did not affect the severity of abdominal aortic aneurysm (A) and survival 
curve (B) between Apoe-/- mice and Tlr9-/-Apoe-/- mice. The severity of abdominal aortic aneurysm 
and survival curve between the two strains were analyzed by Mann-Whitney U test and 
Kaplan-Meier method with log-rank test, respectively. 
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Figure S2. iODN2088, a specific antagonist to TLR9, inhibits TLR9 activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
qPCR analysis demonstrated that iODN2088, an inhibitory oligonucleotide for TLR9, blocked 
inflammatory molecule expression induced by ODN1826. *P < 0.05. All comparisons between 
iODN2088-treated group and Ctrl-iODN-treated group were performed with Mann-Whitney U test. 
All values are mean ± SEM. 
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Figure S3. TLR9 ligation promotes p38 MAPK activation in Apoe-/- macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Western blotting analysis showed that ODN1826 increased the phosphorylation of p38 MAPK in 
Apoe-/- macrophages, which was blocked in the presence of iODN2088. Both ODN1826 and 
iODN2088 did not have any effect in Tlr9-/-Apoe-/- mice. *P<0.05, and ***P<0.001. Comparison 
between ODN1826-treated group and Ctrl-ODN1826-treated group and comparison between 
iODN2088-treated group and Ctrl-iODN-treated group were performed with Mann-Whitney U test. 
All values are mean ± SEM. 
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Figure S4. Tlr9-/-Apoe-/- mice had larger atherosclerotic lesions compared with Apoe-/- mice 
under vehicle infusion condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic deletion of TLR9 promoted atherosclerotic lesion development in vehicle-infused Apoe-/- 
mice (n = 12-18). Scale bar; 1 mm. ***P<0.001. Comparison between Tlr9-/-Apoe-/- mice and 
Apoe-/- mice was performed with Mann-Whitney U test. All values are mean ± SEM. 
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